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Background: Antiphospholipid syndrome (APS) in pregnancy is characterized by the 
presence of maternal autoantibodies in association with recurrent fetal loss and 
severe obstetric complications such as prematurity, intrauterine growth retardation, 
or placental insufficiency. This study aimed to assess the perinatal outcomes in 
neonates born to mothers with APS.
Methods: The medical records of pregnant women with APS and their offspring were 
retrospectively collected between January 1997 and July 2007. Maternal and perina-
tal histories including demographic data, medications, obstetric histories, and neona-
tal clinical manifestations and laboratory data were analyzed.
Results: Eleven women with a diagnosis of primary APS were included. Eight of these 
patients had experienced frequent spontaneous abortions (72.7%), and four had unex-
plained fetal deaths (36.3%). None of them had vascular thrombosis. Specific 
autoimmune antibodies were detected, including anticardiolipin antibody (n = 6), 
anti-β2 glycoprotein I (n = 3), and antiphospholipid antibody (n = 7). Among the preg-
nancies, five had preterm births (45.4%), two had intrauterine growth retardation 
(18.1%), and one had intrauterine fetal demise (9.1%). Thrombocytopenia was noted in 
three babies, all of whose mothers had lower platelet counts. One patient with neo-
natal thrombocytopenia developed intracranial hemorrhage, seen on brain images.
Conclusions: This limited study suggests that neonates born to mothers with primary 
APS are at risk of prematurity, being small for gestational age, and having thrombo-
cytopenia. Further large, prospective studies are required to better define the peri-
natal outcomes.
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1. Introduction
Antiphospholipid syndrome (APS) is defined as a 
prothrombotic disorder characterized by repeated 
vascular thrombosis and recurrent spontaneous preg-
nancy loss in the presence of circulating antiphospho-
lipid antibodies. It causes significant complications 
in obstetrics and pregnancy, including maternal 
thrombosis, fetal growth retardation, prematurity, 
infertility, and recurrent miscarriage. However, when 
properly managed, APS represents one of the few 
treatable causes of pregnancy loss.1 Various adverse 
effects on the fetus and newborn baby have been 
reported, the most common of which are prematu-
rity and its associated complications.2,3 Isolated 
neonatal thrombosis has also been noted, mostly 
involving arterial vasculature in the brain.4,5 There 
is limited information available concerning the peri-
natal outcomes of neonates born to mothers with 
primary APS in Taiwan. This study therefore aimed 
to explore the perinatal outcomes in neonates born 
to mothers with APS at a medical center located in 
northern Taiwan.
2. Patients and Methods
We conducted a retrospective review of the hospital 
data base at the National Taiwan University Hospital, 
Taipei, Taiwan, to identify pregnant women diagnosed 
with APS during the period from January 1997 to 
July 2007. The diagnosis of APS was made accord-
ing to the revised International Classification Criteria 
established in 2006,6 which are based on both clini-
cal manifestations and laboratory findings. Because 
there is no specific ICD 9 code for APS, we used sev-
eral codes to identify possible candidates: 289.8 
(other specified diseases of blood and blood-forming 
organs), 287.3 (autoimmune thrombocytopenia), 
795.7 (other nonspecific immunological findings), 
and 649.3 (coagulation defects complicating preg-
nancy, childbirth, or the puerperium). Medical re-
cords were extensively reviewed after identification 
of the candidates. Patients who fulfilled the newest 
criteria for primary APS were included in this study. 
We excluded patients who had accompanying auto-
immune diseases with antiphospholipid antibodies.
Maternal and perinatal histories (i.e., demo-
graphic data, medications during pregnancy, and 
obstetric histories) and neonatal data (i.e., labo-
ratory findings and imaging studies) were obtained 
from chart records. All patients received screening 
for autoimmune antibodies, including antiphospho-
lipid antibody, IgG and IgM anticardiolipin, and beta-
2-glycoprotein-1 antibody. Maternal hemograms and 
hemostatic profiles were checked within 24 hours 
before delivery. Laboratory and imaging studies were 
performed in the neonates that were admitted to 
the neonatal intensive care unit or intermediate care 
ward. Imaging studies, including brain echo and com-
puterized tomography scans were performed when 
necessary.
3. Results
There were 11 pregnant women fulfilling the crite-
ria for analysis. The age at diagnosis ranged from 
22−37 years, with a median age of 32 years. Among 
their pregnancy morbidities, four patients had un-
explained fetal death beyond the 10th week of preg-
nancy and eight patients had more than three 
consecutive, spontaneous pregnancy losses. Eight of 
them had experienced frequent spontaneous abor-
tions. The mean number of miscarriages was 3.1, 
with an interquartile range of 2.5. None of them had 
experienced preterm pregnancies due to eclamp-
sia, severe pre-eclampsia or placental insufficiency. 
No vascular thrombosis events were found among 
these women. Specific autoimmune antibodies were 
detected in the mothers, including anticardiolipin 
antibody (n = 6), anti-β2 glycoprotein I (n = 3) and 
antiphospholipid antibody without any specific 
mention (n = 7). Hematological profiles and coagu-
lation tests checked just before delivery showed 
that four mothers had thrombocytopenia and three 
had anemia. Medications most commonly taken dur-
ing pregnancy among the 10 patients with available 
histories were aspirin (80%), prednisolone (60%), 
hydroxychloroquine (50%), and low-molecular-weight 
heparin (40%).
There were 12 babies born to these 11 mothers, 
including one pair of twins and one intrauterine fetal 
demise. Among the 11 surviving infants, six were 
low birth weight (LBW) (54.5%), five were preterm 
births (45.4%), and two had intrauterine growth 
retardation (18.2%).7 Eight patients were delivered 
by Cesarean section and three were normal, smooth 
deliveries. The reasons for Cesarean section in-
cluded twin pregnancy, fetal distress, chemotherapy 
for maternal breast cancer, previous uterine sur-
gery, prematurity, and elective scheduling. Among 
the five preterm babies, two were small for gesta-
tional age (SGA). One was symmetric and the other 
was asymmetric. Five babies were admitted to the 
neonatal intensive care unit due to prematurity and/
or respiratory distress. Regarding neonatal outcomes, 
two babies had respiratory distress syndrome, 
three had patent ductus arteriosus, two of whom 
received surgical ligation, and two had low grade 
retinopathy of prematurity. Among the five babies 
with available hematological studies, two had ane-
mia, one had leucopenia and one had prolonged 
activated partial thromboplastin time. In addition, 
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thrombocytopenia was noted in three babies, all of 
whose mothers also had lower platelet counts. One 
patient with neonatal thrombocytopenia developed 
intracranial hemorrhage, identified by ultrasound 
and computerized tomography.
4. Discussion
APS has long been recognized as a cause of miscar-
riage and infertility, and many clinicians consider 
APS to be the most common thrombotic disorder 
causing recurrent miscarriage. In an historical as-
sessment evaluating women with APS, Oshiro et al 
found that 80% of their patients had suffered from 
at least one miscarriage.8 Borrelli et al also re-
ported that 60% of their patients who had habitual 
unexplained miscarriages harbored APS.9 In experi-
mental, pregnant animal models, antiphospholipid 
antibodies have been shown to play a pathogenic 
role in the development of placental insufficiency 
and miscarriages.10 Furthermore, in vitro studies 
have also shown that antiphospholipid autoanti-
bodies can bind to trophoblast cells to activate the 
complement cascade that mediates placental in-
jury and causes fetal loss and growth restriction.11,12 
Untreated primiparae with a high titer of IgG anti-
bodies have around a 28−30% probability of fetal 
loss, which often occurs in the second trimester.13 
Except for obstetric complications, our study re-
vealed no vascular ischemia in the mothers, although 
deep venous thrombosis, pulmonary embolism and 
stroke were not uncommon events during their preg-
nancies. According to this limited retrospective 
study, pregnancy need not be discouraged in women 
with a history of APS, though their pregnancies 
should be considered to be at risk of preterm birth 
and/or small for gestational age babies.
Various unfavorable effects of maternal APS on 
the fetus and newborn baby have been reported. The 
incidence of prematurity among infants born to 
mothers with APS has been reported to be around 
10−24%, and a high incidence of SGA has also been 
revealed.2,3 Prematurity and SGA may result from in-
sufficient placental vascularization owing to com-
plement activation by antiphospholipid antibodies. 
Placental damage has been reportedly associated 
with early embryonic mortality, fetal tissue injury 
and intrauterine growth restriction.14 Tincani et al 
performed a controlled study in patients with mat-
ched gestational ages and pregnancy complications 
to verify if the presence of antiphospholipid antibod-
ies was linked to specific risks for the fetus and ne-
onate. They found no significant difference in the 
incidence of neonatal complications between the 
groups. Their results further suggested that the main 
problem in pregnancies with primary APS see med to 
be prematurity, with a rate of up to 18.8%.15 Neonatal 
thrombosis involving the brain and other regions have 
been reported in neonates born to mothers with APS, 
but the pathogenesis remains unclear.5,16 It may be 
due to transplacental antiphospholipid antibodies or 
other embryonic vascular accidents.
Thrombocytopenia is frequently present in pa-
tients with antiphospholipid bodies, with an inci-
dence ranging from 20−40%.17 Likewise, a high 
prevalence of thrombocytopenia was noted in our 
study: Four of 11 (36.3%) mothers with primary APS 
had thrombocytopenia. Thrombocytopenia was also 
noted in three babies, all of whose mothers had lower 
platelet counts. One of these newborns with throm-
bocytopenia developed intracranial hemorrhage, but 
fortunately, the other two babies were asymptoma-
tic. The thrombocytopenia is usually mild, and se-
vere thrombocytopenia is most often seen in patients 
with catastrophic APS and those with thrombotic 
thrombocytopenic purpura. Godeau et al reported 
a higher prevalence of serum platelet antibodies in 
patients with thrombocytopenia.18 The pathogen-
esis of thrombocytopenia is unclear, and the pro-
posed mechanisms include coexisting antibodies to 
platelet glycoproteins, or antiphospholipid antibod-
ies against platelet membranes.19,20 Most of these 
platelet-specific autoantibodies are IgG antibodies 
that may cross the placenta to affect babies born 
to mothers with primary APS.
Some limitations of this retrospective study should 
be noted. No specific ICD code has been established 
for APS, so we may have underestimated its true in-
cidence. It is likely that many mothers with APS who 
received medical treatment and had successful preg-
nancies and normal deliveries in our hospital were 
not included. Some medical records used in the ret-
rospective chart review were incomplete, and lacked 
data such as maternal antibody titers determined 
during pregnancy. In addition, laboratory tests and 
imaging studies were only performed in the neonates 
who were admitted for evaluation. It cannot be con-
cluded that those who were not tested were normal.
The results of this small, retrospective population 
study, suggest that neonates born to mothers with 
primary APS are at risk of being preterm, of being 
SGA babies, and of developing thrombocytopenia 
after birth. Further prospective studies should be car-
ried out involving larger numbers of patients, in order 
to clarify the impacts of various maternal autoim-
mune antibody levels on neonatal outcomes.
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